September 23, 2002Circulation
Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups
Why the study?
Does clopidogrel reduce cardiovascular death, myocardial infarction, or stroke in patients with non-ST-elevation acute coronary syndromes across various TIMI risk groups?
Population
12,562 patients with non-ST-elevation acute coronary syndromes presenting within 24 hours after the onset of…
Comparison
Clopidogrel in addition to aspirin for 3 to 12… vs Placebo in addition to aspirin for 3 to 12 months
Design
RCT, randomized
Follow-up
3 to 12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports adding clopidogrel to aspirin across NSTE-ACS TIMI strata; reinforces consistent benefit in this RCT.
Structured PICO
Does clopidogrel reduce cardiovascular death, myocardial infarction, or stroke in patients with non-ST-elevation acute coronary syndromes across various TIMI risk groups?
P
Population
12,562 patients with non-ST-elevation acute coronary syndromes presenting within 24 hours after the onset of symptoms
I
Intervention
Clopidogrel (300 mg followed by 75 mg daily) in addition to aspirin for 3 to 12 months
C
Comparator
Placebo in addition to aspirin for 3 to 12 months
O
Outcome
Composite outcome of cardiovascular death, myocardial infarction, or strokecomposite
The addition of clopidogrel to aspirin consistently reduces cardiovascular events in patients with non-ST-elevation acute coronary syndromes across all TIMI risk strata.
Cite This Study
Budaj et al. (2002) studied this question.